Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Virus-like particle vaccines

A virus-like, virus-like technology, applied to viruses, vaccines, viral peptides, etc., can solve problems such as interference with antigen folding, failure to maintain antigens and antigen fragments, and insufficient maintenance of the original antigen configuration to achieve strong immunogenicity.

Inactive Publication Date: 2017-04-19
MEDIGEN BIOTECH
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The configuration of this monomer interferes with the folding of the antigen, especially when the antigen is large or its three-dimensional configuration contains more complex folding patterns, and because they do not sufficiently maintain the original antigen configuration, most monomeric fusion proteins do not success
Antigen conformations that contain or resemble the original conformation play an important role in immune system recognition, however many antigens and antigen fragments do not maintain or sufficiently resemble their original conformation when antigens or antigen fragments are presented as monomeric fusion proteins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Virus-like particle vaccines
  • Virus-like particle vaccines
  • Virus-like particle vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0177] Embodiment 1: Construction of virus-like particle template

[0178] The virus-like particle template ( FIG. 1 ) was synthesized in plasmid pUC57 with GenScript, and the sequence was optimized for codons suitable for yeast. The fragment of the virus-like particle template was subcloned into the yeast expression plasmid vector pPICZ A using EcoRI (5'-end) and SacII (3'-end) cleavage, and the expression was regulated by the methanol-inducible AOX1 promoter. The sequence encoding the N-terminal viral structural protein (VP1) was cloned into the template using the XhoI+Nhel paired restriction sites at the 5' and 3' ends. The sequence encoding the N-terminal linker (linker 1 ) was cloned into the template using the NheI+NdeI paired restriction sites at the 5' and 3' ends. The sequence encoding the antigen was cloned into the template using the NdeI+PstI paired restriction sites at the 5' and 3' ends. The sequence encoding the C-terminal linker (linker 2) was cloned into the...

Embodiment 1A

[0186] Example 1A: Construction of S-VP1-S

[0187] The coding region of S-VP1-S was synthesized in plasmid pUC57 with GenScript (see Figure 9 ), and the sequence was optimized for codons suitable for the E.coli host. The fragment of the virus-like particle template was subcloned into the plastid vector pCRT7NT (Invitrogen) by PCR, and the expression was regulated by the IPTG-induced T7 promoter. This technique was used to produce the recombinant proteins of Examples 1-109 in the table above.

Embodiment 2

[0188] Example 2: Yeast Transformation

[0189] Recombinant plastid DNA was linearized with PmeI restriction enzyme (NEB Company), and (Macherey-Nagel) clean up the recombinant plastids for subsequent transformations. By LiCl method and according to EasySelect TM According to the operation manual of the Pichia Expression Kit (Invitrogen), 5-10 μg of linearized plastid DNA was transformed into the Pichia host strain GS115. The transformant was inoculated on YPDS plate medium containing 50 μg / ml bleomycin (Invivogen Company) (1% (w / v) yeast extract, 2% (w / v) tryptone, 2% (w / v) v) Glucose and 1.5% (w / v) agar). Colonies resistant to bleomycin were screened and the insert was confirmed by colony PCR using the following primers: 5'AOX1 primer: 5'-GACTGGTTCCAATTGACAAGC-3'(SEQ ID NO:28); 3'AOX1 primer: 5'-GCAAATGGCATTCTGACATCC-3' (SEQ ID NO: 29).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and / or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

Description

[0001] This case claims priority to U.S. Provisional Application No. 62 / 034,475, filed August 7, 2014, which is incorporated herein by reference. technical field [0002] The present invention relates to the fields of virology, immunology, microbiology, molecular biology, biochemistry, and genetics. In particular, the invention relates to immunogenic compositions comprising virus-like particles comprising a fusion protein comprising an antigenic peptide sequence of a pathogen, a viral structural peptide, and, optionally, one or more Linker, wherein the viral structural peptide itself may or may not be immunogenic, if a linker is included, it is linked with the antigen or antigen fragment and the viral structural protein. The invention also provides methods for eliciting an immune response with the fusion proteins of the invention. Background technique [0003] Vaccines generally include attenuated viruses, or other attenuated microorganisms, or combinations thereof. Althou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N7/04A61K39/29A61K39/145A61K39/125A61K39/12A61P31/14A61P31/20A61P31/16
CPCA61K39/12A61K2039/55572A61K2039/70C12N2760/16134C12N2770/28134C12N2770/32334C12N2770/32371C12N2720/12323C12N2730/10123C12N2760/16123C12N2770/28123C12N2770/32323A61K2039/5258C07K14/005C07K2319/40C12N2730/10134C12N2770/16023C12N2770/16034A61P31/14A61P31/16A61P31/20Y02A50/30A61K39/292A61K2039/627A61K2039/645C12N7/00C12N2730/10151C12N2730/10171C12N2770/16042C12N2770/16051C12N2770/16071
Inventor 林阳生郑金益江雅铃陈明正K-T A·赖杨智雅
Owner MEDIGEN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com